REG - Retroscreen Vlgy Grp - Result of General Meeting <Origin Href="QuoteRef">RVG.L</Origin>

hVIVOAnnouncement

29/10/2014 07:15

RNS Number : 5225Q
Retroscreen Virology Group PLC
01 September 2014
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, NEW ZEALAND, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY JURISDICTION IN WHICH SUCH PUBLICATION OR DISTRIBUTION IS PROHIBITED. 
For immediate release 14.00: 1 September 2014
RETROSCREEN VIROLOGY GROUP PLC
("Retroscreen" or the "Company")
RESULT OF GENERAL MEETING
Retroscreen Virology Group plc (AIM: RVG), which is pioneering its hVIVO platform of human models of disease, is pleased to announce that the resolutions put to shareholders at today's General Meeting in connection with the Placing announced by the Company on 14 August 2014, were duly passed. 
Following the passing of the resolutions at the General Meeting, 12,923,077 new Ordinary Shares have been allotted to existing and new investors, conditional upon the admission of such Ordinary Shares to trading on AIM. It is expected that settlement will occur, admission to trading on AIM will become effective and dealings will commence in respect of the 12,923,077 new Ordinary Shares at 8.00am on 2 September 2014.
Following admission of the 12,923,077 new Ordinary Shares to trading on AIM, the total number of Ordinary Shares with voting rights in issue will be 67,646,898 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules. 
Upon admission, the new Ordinary Shares will be issued, credited as fully paid and will rank pari passu in all respects with the existing Ordinary Shares of the Company. 
For further information please contact: 
Retroscreen Virology Group plc +44 207 756 1300
Kym Denny (CEO)
Graham Yeatman (FD) 
Numis Securities Limited +44 207 260 1000 
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)
Important Notice 
This announcement has been prepared solely to provide information about the Placing and it does not constitute, or form part of, any offer or invitation to purchase, underwrite or otherwise acquire Ordinary Shares, or the solicitation of any such offer. Without limiting the foregoing statement, this announcement does not constitute an offer of Ordinary Shares for sale in the United States. The Ordinary Shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the Securities Act), or the laws of any state, and may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state laws. Retroscreen Virology Group plc does not intend to register the Ordinary Shares under the Securities Act. No public offering of Ordinary Shares will be made in the United States.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
ROMXFLFBZKFBBBF